Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy

Abstract

<jats:title>Abstract</jats:title><jats:p>The purpose of this study was to investigate the effects of <jats:italic>SLC22A2</jats:italic> 808G>T polymorphism and trough concentrations (C<jats:sub>0</jats:sub>) of bosutinib on serum creatinine in 28 patients taking bosutinib. At 1, 3, 6, 12, 24, and 36 months after administration, analysis of bosutinib C<jats:sub>0</jats:sub> and creatinine was performed at the same time of day. Significant correlations were observed between bosutinib C<jats:sub>0</jats:sub> and the change rate of serum creatinine or the estimated glomerular filtration rate (eGFR; <jats:italic>r</jats:italic> = 0.328, <jats:italic>P</jats:italic> < 0.001 and <jats:italic>r</jats:italic> = − 0.315, <jats:italic>P</jats:italic> < 0.001, respectively). These correlations were particularly high in patients having the <jats:italic>SLC22A2</jats:italic> 808G/G genotype (<jats:italic>r</jats:italic> = 0.345 and <jats:italic>r</jats:italic> = − 0.329, respectively); however, in patients having the 808T allele, there were no significant differences. In multivariate analyses, the <jats:italic>SLC22A2</jats:italic> 808G/G genotype, patient age, bosutinib C<jats:sub>0</jats:sub> and second-line or later bosutinib were independent factors influencing the change rate of creatinine. Bosutinib elevated serum creatinine through organic cation transporter 2 (OCT2). We observed a 20% increase in serum creatinine with a median bosutinib C<jats:sub>0</jats:sub> of 63.4–73.2 ng/mL. Periodic measurement of serum creatinine after bosutinib therapy is necessary to avoid progression to severe renal dysfunction from simple elevation of creatinine mediated by OCT2 following bosutinib treatment.</jats:p>

Journal

References(19)*help

See more

Related Projects

See more

Details 詳細情報について

Report a problem

Back to top